The ADA has created a new Code on Dental Procedures and Nomenclature (CDT) for Exparel, a bupivacaine liposome injectable suspension from Pacira Pharmaceuticals.
The new CDT code, D9613, will go into effect on January 1, 2019.
In addition, the U.S. Centers for Medicare and Medicaid Services (CMS) has created a billing code for Exparel. The CMS code, C9290, will also go into effect on January 1, and it will reimburse Exparel at about the average sales price, according to Pacira.
